Assessment of Response and Safety of Bulevirtide Treatment in Patients With Chronic Delta Virus Infection

CompletedOBSERVATIONAL
Enrollment

160

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

July 30, 2025

Conditions
Evaluate Response to Treatment Both Biochemically and Virologically to Determine the Safety and Effectiveness of Bulevirtide Therapy in HDV Patients
Interventions
DIAGNOSTIC_TEST

virological tests diagnostic tests

"The parameters collected will include blood sugar, HbA1c, complete blood count, lipid profile (total cholesterol, LDL, HDL, triglycerides), liver profile (ALT, AST, total and fractionated bilirubin, alkaline phosphatase, GGT) and renal profile (creatinine, azotemia), electrophoretic protein picture. Additionally, specific data for HDV and HBV infection will be collected, including HBsAg, anti-HBs, anti-HBc, HBV-DNA, and HDV-RNA. The glomerular filtration rate shall be calculated using the formula CKD-EPI.~• Instrumental Tests: Results of abdominal ultrasounds, Fibroscan®/CAP for the evaluation of liver fibrosis"

Trial Locations (1)

86100

Università degli studi del molise, Campobasso

All Listed Sponsors
lead

University of Molise

OTHER